Previous 10 | Next 10 |
Immunomedics (NASDAQ: IMMU ) initiated with Overweight rating and $28 price target at Cantor Fitzgerald. More news on: Immunomedics, Inc., SCYNEXIS, Inc., AbbVie Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SCYNEXIS (NASDAQ: SCYX ): Q2 GAAP EPS of -$0.16 beats by $0.03 . More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERSEY CITY, N.J. , Aug. 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended June 30, 2019 , and provi...
JERSEY CITY, N.J. , July 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global G...
SCYNEXIS' Announcement SCYNEXIS (NASDAQ: SCYX ) is a micro cap biotech company that develops novel anti-fungal treatments. On Tuesday, July 24, the company announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Asses...
Jounce Therapeutics (NASDAQ: JNCE ) +34% on revised Celgene collaboration . More news on: Jounce Therapeutics, Inc., Teradyne, Inc., Vislink Technologies, Inc., Stocks on the move, Read more ...
JERSEY CITY, N.J. , July 24, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has reached an agreement with the U.S. Food and Drug Adm...
I had an hour phone conversation with Scynexis ( SCYX ) CEO Marco Taglietti last week. Key takeaways are summarized below. Data so far shows that Scynexis clearly has a novel antifungal asset, which can be used in both outpatient and hospitalized patient settings. The oral form of Ibrexafung...
Shares of SCYNEXIS ( SCYX ) have risen by 25% since my January update piece highlighted encouraging data from the FURI study and reiterated my expectations of near-term upside. The stock offered a nice run-up opportunity, with shares rising as high as 75% before pulling back over the past fe...
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...